diclofenac has been researched along with tamoxifen in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 19 (67.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Augustyns, K; Baán, A; Caljon, G; Kiekens, F; Maes, L; Matheeussen, A; Salado, IG; Van der Veken, P; Verdeyen, T | 1 |
| Caljon, G; Cappoen, D; Claes, P; Cools, F; Cos, P; De Kimpe, N; de Macedo, MB; Delputte, P; Holvoet, F; Maes, L; Mangelinckx, S; Matheeussen, A; Meiresonne, T; Neyrolles, O; Piller, T; Semina, E; Torfs, E; Van Calster, K | 1 |
| Beham, A; Kerbl, R; Lackner, H; Schwinger, W; Urban, C | 1 |
| Karami-Tehrani, F; Mokarram, P; Salami, S | 1 |
| Benesch, M; Dornbusch, HJ; Lackner, H; Moser, A; Raith, J; Schwinger, W; Sovinz, P; Triebl-Roth, K; Urban, C | 1 |
| Maskaoui, K; Zhou, JL | 1 |
| Allu, S; Bethke, KP; Chatterton, RT; Hansen, NM; Helenowski, I; Ivancic, D; Kenney, K; Khan, SA; Lee, O; Muzzio, M; Scholtens, D; Shidfar, A; Sullivan, ME | 1 |
| Honda, H; Ito, Y; Kawamoto, T; Morita, O | 1 |
| Bridges, LR; Elbrecht, D; Funk, C; Hickman, JJ; Long, CJ; Martin, C; McAleer, CW; Roth, AB; Rumsey, JW; Sasserath, T; Schnepper, M; Schuler, F; Shuler, ML; Wang, Y | 1 |
| Hall, SD; Mohutsky, MA; Posada, MM; Taylor, LS; Tres, F | 1 |
3 review(s) available for diclofenac and tamoxifen
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for diclofenac and tamoxifen
| Article | Year |
|---|---|
Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Diclofenac; Drug Evaluation, Preclinical; Female; Gels; Humans; Mammary Glands, Animal; Middle Aged; Norpregnadienes; Outcome Assessment, Health Care; Pilot Projects; Preoperative Period; Random Allocation; Rats, Nude; Tamoxifen | 2015 |
24 other study(ies) available for diclofenac and tamoxifen
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives.
Topics: Animals; Disease Models, Animal; Humans; Mice; Structure-Activity Relationship; Triazines; Tropolone; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2018 |
The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzophenanthridines; Cell Line; Dose-Response Relationship, Drug; Humans; Hydrocarbons, Fluorinated; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2019 |
Noncytotoxic drug therapy in children with unresectable desmoid tumors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Diclofenac; Drug Therapy, Combination; Female; Fibromatosis, Aggressive; Humans; Infant; Mandibular Neoplasms; Remission Induction; Tamoxifen; Thoracic Neoplasms | 1997 |
Competition of tamoxifen with thyroxine for TBG binding: ligand binding assay and computational data.
Topics: Binding, Competitive; Diclofenac; Furosemide; Humans; Mefenamic Acid; Models, Molecular; Molecular Conformation; Tamoxifen; Thyroxine; Thyroxine-Binding Proteins | 2001 |
Multimodal treatment of children with unresectable or recurrent desmoid tumors: an 11-year longitudinal observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Diclofenac; Female; Fibromatosis, Aggressive; Humans; Infant; Longitudinal Studies; Magnetic Resonance Imaging; Male; Methotrexate; Neoplasm Recurrence, Local; Surgical Procedures, Operative; Tamoxifen; Vinblastine | 2004 |
Colloids as a sink for certain pharmaceuticals in the aquatic environment.
Topics: Carbamazepine; Colloids; Diclofenac; Environmental Restoration and Remediation; Fresh Water; Indomethacin; Meclofenamic Acid; Pharmaceutical Preparations; Phenethylamines; Propranolol; Sewage; Sulfamethoxazole; Tamoxifen; Thioridazine; Water Pollutants, Chemical | 2010 |
Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics.
Topics: Administration, Oral; Animals; Chlorpromazine; Cholestasis; Cholesterol; Cyclosporine; Diclofenac; Dose-Response Relationship, Drug; Flutamide; Gene Expression; Humans; Imipramine; Inflammation; Ketoconazole; Liver; Methyltestosterone; Oxidative Stress; Rats; Risk Assessment; Sulindac; Tamoxifen; Toxicogenetics | 2017 |
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics.
Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Diclofenac; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Lab-On-A-Chip Devices; Tamoxifen; Verapamil | 2019 |
The Effect of Promiscuous Aggregation on in Vitro Drug Metabolism Assays.
Topics: Carvedilol; Colloids; Cytochrome P-450 Enzyme System; Diclofenac; Dihydropyridines; Drug Interactions; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Kinetics; Metabolic Clearance Rate; Microsomes, Liver; Phenacetin; Recombinant Proteins; Solvents; Tamoxifen | 2019 |